In the most recent earnings call Novartis said it has 15 major launches spanning the next three years. That equals many more opportunities to compensate for declining sales of former blockbusters, like cancer drug Gleevec, that have been hurt by generic competition. Novartis' stock has slipped 19% this year, trading near its lowest level in relation to earnings in about a year.